[I just posted this on Thyroid UK forum but as I specifically mention B12, and there have been several mentions of B12 together with bone here very recently, am simply re-posting here.]
I think we might see loss of height as a marker. But as I read through this and some of the newspaper versions I was struck:
Strenuous exercise was a "good thing". But how did they separate that out between those who have a condition which means ability to do strenuous exercise is severely limited or totally removed?
They are right to suggest looking as a marker rather than a cause. But:
We know that B12 deficiency affects bone.
We know that thyroid hormone deficiency or excess affects bone.
Why do we miss so many cases of both?
Epidemiology
Original research
Loss of height predicts total and cardiovascular mortality: a cohort study of northern European women
Abstract
Objective To examine height changes in middle-aged northern European women in relation to overall and cardiovascular mortality.
Design Population-based cohort studies with longitudinally measured heights and register-based mortality.
Setting Sweden and Denmark.
Participants Population-based samples of 2406 Swedish and Danish women born on selected years in 1908–1952, recruited to baseline examinations at ages 30–60, and re-examined 10–13 years later.
Main outcome measure Total and cardiovascular disease (CVD) specific mortality during 17–19 years of follow-up after last height measure.
Results For each 1 cm height loss during 10–13 years, the HR (95% CI) for total mortality was 1.14 (1.05 to 1.23) in Swedish women and 1.21 (1.09 to 1.35) in Danish women, independent of key covariates. Low height and high leisure time physical activity at baseline were protective of height loss, independent of age. Considering total mortality, the HR for major height loss, defined as height loss greater than 2 cm, were 1.74 (1.32 to 2.29) in Swedish women and 1.80 (1.27 to 2.54) in Danish women. Pooled analyses indicated that height loss was monotonically associated with an increased mortality, confirming a significant effect above 2 cm height loss. For cause-specific mortality, major height loss was associated with a HR of 2.31 (1.09 to 4.87) for stroke mortality, 2.14 (1.47 to 3.12) for total CVD mortality and 1.71 (1.28 to 2.29) for mortality due to causes other than CVD.
Conclusion Height loss is a marker for excess mortality in northern European women. Specifically the hazard of CVD mortality is increased in women with height loss during middle age, and the results suggest that the strongest cause-specific endpoint may be stroke mortality. The present findings suggest attention to height loss in early and mid-adulthood to identify women at high risk of CVD, and that regular physical activity may prevent early onset height loss.
